Trimethadione: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|An anticonvulsant medication}} | |||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 477002123 | |||
| IUPAC_name = 3,5,5-Trimethyl-2,4-oxazolidinedione | |||
| image = Trimethadione.svg | |||
| width = 200px | |||
| tradename = Tridione | |||
| pregnancy_AU = D | |||
| pregnancy_US = D | |||
| legal_status = Rx-only | |||
| routes_of_administration = Oral | |||
| bioavailability = 100% | |||
| protein_bound = 0% | |||
| metabolism = Hepatic | |||
| elimination_half-life = 16-24 hours | |||
| excretion = Renal | |||
| CAS_number = 127-48-0 | |||
| ATC_prefix = N03 | |||
| ATC_suffix = AD01 | |||
| PubChem = 5563 | |||
| DrugBank = DB00347 | |||
| ChemSpiderID = 5363 | |||
| UNII = 3Z8Z60B3YX | |||
| KEGG = D00382 | |||
| ChEBI = 4598 | |||
| ChEMBL = 1201310 | |||
| C=6 | |||
| H=9 | |||
| N=1 | |||
| O=2 | |||
| smiles = CC1(C)C(=O)N(C)C(=O)O1 | |||
| StdInChI = 1S/C6H9NO2/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3 | |||
| StdInChIKey = ZLJMRSGQIGNYQG-UHFFFAOYSA-N | |||
}} | |||
'''Trimethadione''' is a medication used primarily in the treatment of [[epilepsy]], specifically for [[absence seizures]]. It was one of the first anticonvulsant drugs developed and was introduced in the 1940s. Trimethadione is known by the brand name '''Tridione'''. | |||
Trimethadione | ==Medical uses== | ||
Trimethadione is used to control [[absence seizures]], which are a type of [[generalized seizure]] characterized by brief lapses in consciousness. It is not effective for other types of seizures such as [[tonic-clonic seizures]] or [[partial seizures]]. | |||
== | ==Mechanism of action== | ||
The exact mechanism by which trimethadione exerts its anticonvulsant effects is not fully understood. It is believed to work by modulating the activity of [[voltage-gated calcium channels]] in the [[thalamus]], which play a key role in the generation of absence seizures. | |||
==Side effects== | |||
Common side effects of trimethadione include [[drowsiness]], [[dizziness]], and [[nausea]]. More serious side effects can include [[blood dyscrasias]], [[liver toxicity]], and [[dermatological reactions]]. Long-term use can lead to [[gingival hyperplasia]] and [[hirsutism]]. | |||
== | ==Contraindications== | ||
Trimethadione is contraindicated in patients with a history of [[hypersensitivity]] to the drug. It is also not recommended for use during [[pregnancy]] due to the risk of [[teratogenicity]]. | |||
==History== | |||
Trimethadione was first synthesized in the 1940s and was one of the earliest anticonvulsant drugs used to treat absence seizures. It has largely been replaced by newer medications such as [[ethosuximide]] and [[valproic acid]], which have more favorable side effect profiles. | |||
==Related pages== | |||
* [[Ethosuximide]] | |||
* [[Valproic acid]] | |||
* [[Epilepsy]] | |||
* [[Seizure types]] | |||
== | ==References== | ||
{{Reflist}} | |||
[[Category:Anticonvulsants]] | [[Category:Anticonvulsants]] | ||
[[Category: | [[Category:Oxazolidinediones]] | ||
[[Category: | [[Category:Epilepsy treatments]] | ||
Revision as of 12:00, 9 February 2025
An anticonvulsant medication
| Trimethadione | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | Oral |
| Pregnancy category | |
| Bioavailability | 100% |
| Metabolism | Hepatic |
| Elimination half-life | 16-24 hours |
| Excretion | Renal |
| Legal status | Rx-only |
| CAS Number | 127-48-0 |
| PubChem | 5563 |
| DrugBank | DB00347 |
| ChemSpider | 5363 |
| KEGG | D00382 |
Trimethadione is a medication used primarily in the treatment of epilepsy, specifically for absence seizures. It was one of the first anticonvulsant drugs developed and was introduced in the 1940s. Trimethadione is known by the brand name Tridione.
Medical uses
Trimethadione is used to control absence seizures, which are a type of generalized seizure characterized by brief lapses in consciousness. It is not effective for other types of seizures such as tonic-clonic seizures or partial seizures.
Mechanism of action
The exact mechanism by which trimethadione exerts its anticonvulsant effects is not fully understood. It is believed to work by modulating the activity of voltage-gated calcium channels in the thalamus, which play a key role in the generation of absence seizures.
Side effects
Common side effects of trimethadione include drowsiness, dizziness, and nausea. More serious side effects can include blood dyscrasias, liver toxicity, and dermatological reactions. Long-term use can lead to gingival hyperplasia and hirsutism.
Contraindications
Trimethadione is contraindicated in patients with a history of hypersensitivity to the drug. It is also not recommended for use during pregnancy due to the risk of teratogenicity.
History
Trimethadione was first synthesized in the 1940s and was one of the earliest anticonvulsant drugs used to treat absence seizures. It has largely been replaced by newer medications such as ethosuximide and valproic acid, which have more favorable side effect profiles.
Related pages
References
<references group="" responsive="1"></references>